Personalized mRNA Vaccine Shows Promise in Reducing Melanoma Recurrence

Kathmandu— Moderna and Merck have announced promising results from a late-stage clinical trial of an individualized mRNA cancer vaccine, Intismeran, which significantly reduced the risk of melanoma recurrence and tumor spread. The treatment combines mRNA technology with immunotherapy drug Keytruda to train patients’ immune systems to target specific mutations in cancer cells. These interim findings […]